FBRX Company Profile and Key Details

Forte Biosciences, Inc. (NASDAQ:FBRX) closed at $26.52 USD, losing -$0.77 (-2.82%) from the previous close of $27.29. The stock is currently mid-range between its 52-week high and low $6.19 and $35.80. With a market capitalization of about $368.25 million, Forte Biosciences, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~3.20). Key stats such as the average daily volume over the past year has been around 275.58 thousand shares, volume is running light vs its 52-week average. Headquartered in Dallas, TX, Forte Biosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Paul A. Wagner, the company employs approximately 14 people and listed since April 13, 2017. Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States.

Short-term trend indicators are bearishly aligned (SMA20 -2.54%, SMA50 1.05%, SMA200 75.26%). The stock’s 14-day RSI is 49.41 (neutral), while the ATR of 2.8 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -17.86% below its high and over 497.14% above its low. Average 10-day trading volume of 194.46 thousand shares is below the 3-month average of 267.42 thousand, indicating normal recent market interest.

Forte Biosciences, Inc. trades at a P/E ratio of -56.79, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 64.6 reflecting a rich premium to book value. The P/FCF stands at -7.29, also below market averages. Compared to sector medians, Forte Biosciences, Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Forte Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.52. This means the shares are trading above this model’s fair value.

Forte Biosciences, Inc. generated EPS of -$4.44 over the past year. Five-year average earnings growth is 24.08%. Wall Street analysts project EPS growth of 29.76% annually over the next five years. The latest quarter delivered EPS of -$1.45. The next quarter is forecast at -$1.18. Next year's EPS is expected at -$8.62. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $75.00 to $61.00. The high target offers 182.81% upside. The low target suggests 130.02% downside. The mean target is $64.60. This offers 143.59% upside. Forte Biosciences, Inc. earnings surprise history is a mixed track record. The quarter that ended March 31, 2026, missed forecasts by 2.11%. The prior quarter beat by -4.45%. Over the last six quarters, Apple has recorded several small beats. These include -32.74% in November 14, 2024.

Forte Biosciences, Inc. has 12.43 million shares outstanding. The public float is 10.22 million shares, elevated short interest at 1.25% of float. This equals 128.75 thousand shares. The short ratio is 2.4 days. Institutional investors hold 89.92% of the float. Insiders own 4.96%. Oliveira Steven Michael holds 2.87 million shares, Wagner Paul A. has 1.82 million shares and Hasnain Faheem has 241.72 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.